EPM2AIP1

Across TCGA pan-cancer cohorts, EPM2AIP1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EPM2AIP1 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EPM2AIP1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EPM2AIP1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where EPM2AIP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.889	0.605	<.001	76	view →
UCEC	OS	Quartile	II,III,IV	0.277	1.000	.005	40	view →
LUAD	OS	Median	III,IV	0.682	0.210	.009	11	view →
PDAC	DFS	Median	III,IV	0.783	0.599	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EPM2AIP1–CCRCC (DFS)

Open the CCRCC breakdown →